Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine.
To establish a method for predicting polymer-drug compatibility as a means to guide formulation development, we carried out physicochemical analyses of polymer-drug pairs and compared the difference in total and partial solubility parameters of polymer and drug. For these studies, we employed a range of biodegradable polymers and the anticancer agent Ellipticine as the model drug. The partial and total solubility parameters for the polymer and drug were calculated using the group contribution method. Drug-polymer pairs with different enthalpy of mixing values were analyzed by physicochemical techniques including X-ray diffraction and Fourier transform infrared. Polymers identified to be compatible [i.e., polycaprolactone (PCL) and poly-beta-benzyl-L-aspartate (PBLA)] and incompatible [i.e., poly (d,l-lactide (PLA)], by the above mentioned methods, were used to formulate Ellipticine. Specifically, Ellipticine was loaded into PBLA, PCL, and PLA films using a solvent casting method to produce a local drug formulation; while, polyethylene oxide (PEO)-b-polycaprolactone (PCL) and PEO-b-poly (d,l-lactide) (PLA) copolymer micelles were prepared by both dialysis and dry down methods resulting in a formulation for systemic administration. The drug release profiles for all formulations and the drug loading efficiency for the micelle formulations were also measured. In this way, we compared formulation characteristics with predictions from physicochemical analyses and comparison of total and partial solubility parameters. Overall, a good correlation was obtained between drug formulation characteristics and findings from our polymer-drug compatibility studies. Further optimization of the PEO-b-PCL micelle formulation for Ellipticine was also performed.
Liu
Jubo
J
Department of Pharmaceutical Sciences, University of Toronto, 19 Russell St, Rom 315G, Toronto, Ontario M5S 2S2 Canada.
Xiao
Yuehua
Y
Allen
Christine
C
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000032:analysis / Q000737:chemistry*; D016503:Drug Delivery Systems / Q000379:methods*; D004611:Ellipticines / Q000008:administration & dosage / Q000032:analysis / Q000737:chemistry*; D008823:Micelles; D011108:Polymers / Q000008:administration & dosage / Q000032:analysis / Q000737:chemistry*
D000970:Antineoplastic Agents; D004611:Ellipticines; D008823:Micelles; D011108:Polymers; C034192:ellipticine